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After increasing from 1995 to 1999, invasive erythro-
mycin-nonsusceptible  Streptococcus pneumoniae rates
per 100,000 decreased 53.6% in children from Baltimore,
Maryland (USA) from 1999 to 2001, which was partially
attributed to strains related to the mefE-carrying England14-
9 clone. The decline in infection rates was likely due to the
pneumococcal 7-valent conjugate vaccine. 
F
rom 1995 to 1999, the prevalence of macrolide resist-
ance among invasive pneumococci doubled to 20% in
the United States (1). The rise in the 1990s was primarily
due to strains with an M phenotype, a surrogate marker for
the mefE gene (1,2). In 1999, children <5 years of age and
white persons had a higher proportion of M phenotype
strains causing invasive disease than did older persons and
black persons (1). Most macrolide-resistant strains in the
United States were also penicillin-nonsusceptible (1);
modeling suggested that strains resistant to both drug
classes would increase without a vaccine or other interven-
tion (3). Since the introduction of the 7-valent pneumococ-
cal conjugate vaccine (PCV7) in 2000, the overall
incidence of macrolide-resistant infections, including
serotype 14 strains, has decreased in Atlanta, Georgia (4).
It is unclear whether these changes are caused by shifts in
a small number of clones. Most drug-resistant infections in
the United States are related to a small number of interna-
tional clones (5).
The Study
The Baltimore metropolitan area is one of the sites in
the Active Bacterial Core system that conducts active, lab-
oratory surveillance for invasive pneumococcal disease.
Approximately 15 million people residing in Maryland,
Georgia, California, Minnesota, Oregon, Tennessee, and
Connecticut were included in the multicenter study (1). In
this study, we calculated the rates of invasive erythromy-
cin-nonsusceptible S. pneumoniae disease, mefE-associat-
ed disease, and disease due to mefE-carrying clones in the
Baltimore metropolitan area in 1995, 1999, and 2001.
These years were chosen to validate the earlier multicenter
study in the Baltimore metropolitan area (1995 and 1999)
and include 1 year after licensure of PCV7 (2001). PCV7
includes serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F. We
also assessed whether the mefE-carrying strains were
equally distributed in all populations, in all locations, and
during both respiratory and nonrespiratory seasons from
1995 to 2001. Cases of invasive pneumococcal disease
with an erythromycin MIC >0.5  µg/mL isolated from
January 1,1995, to December 31, 2001, were included.
Strains with an erythromycin MIC >0.5 µg/mL and peni-
cillin MIC >0.12 µg/mL were defined as erythromycin-
nonsusceptible and penicillin-nonsusceptible S.
pneumoniae, respectively (6). Pneumococcal serotypes
were determined at the Centers for Disease Control and
Prevention by the latex agglutination test and confirmed
with Quellung reaction. The presence of mef and/or ermB
was determined by using a duplex polymerase chain reac-
tion (PCR) (7), and mefA was differentiated from mefE by
PCR-restriction fragment length polymorphisms (8).
Pulsed-field gel electrophoresis (PFGE) was performed on
all strains (9). Dendrograms were created in Bionumerics
(Applied Maths, Sint-Martens-Latem, Belgium) with a
position tolerance of 1.5%. Strains were compared to the
first 25 international clones (http://www.sph.emory.
edu/PMEN/) (7). Multi-locus sequence typing was per-
formed on 87 (24.5%) of the 349 strains (10,11), and
included the spectrum of PFGE patterns. Based on PFGE
patterns with >80% relatedness by dendrogram, and/or 5
identical alleles, strains were classified into sequence type
(ST)-complexes. The following 4 ST-complexes were clas-
sified as the clones in this analysis: ST9-complex (related
to England14-9clone), ST81-complex (related to Spain23F-
1clone), ST156-complex (related to Spain9V-3clone), and
ST236-complex (related to the Taiwan19F-14clone). 
Rates were calculated by using population estimates
from US Census Bureau data for the Baltimore metropoli-
tan area for 1995, 1999, and 2001. Chi-square and Fisher
exact tests were used to compare the proportion of the pop-
ulation with disease in 1995, 1999, and 2001 (SAS 8.2,
SAS Institute, Cary, NC, USA). Cochran-Armitage trend
test was used to compare the proportion of erythromycin-
nonsusceptible S. pneumoniae strains carrying the mefE
gene from 1995 to 2001. Age groups were defined as chil-
dren <5 years of age and persons >5 years of age; races
were defined as persons of white and black race (1);
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Most cases of invasive pneumococcal disease occurred
in 3 geographic regions: 61.0% (2,976/4,885) in Baltimore
City, 18.3% (895/4,885) in Baltimore County, and 9.8%
(480/4,885) in Anne Arundel County. From January 1,
1995, to December 31, 2001, a total of 4,885 pneumococ-
cal cases were detected in the Baltimore metropolitan area,
of which 85.8% (4,192/4,885) were available for MIC test-
ing. Ninety-seven percent (349/360) of the erythromycin-
nonsusceptible S. pneumoniae isolates were available for
further analysis. Of these isolates, 255 (73.1%) carried
only the mefE gene, 61 (17.5%) carried only the ermB
gene, 8 (2.3%) carried both the mefE and ermB genes, 6
(1.7%) carried the mefAgene, and 19 (5.4%) had unknown
resistance mechanisms. All isolates carrying both the ermB
and mefE genes were serogroup 19 strains that were relat-
ed to the Taiwan19F-14 clone. The mefA-carrying strains
were either serotype 6B or serotype 14. The serotype 6B
strains, belonging to ST146, were detected in Baltimore
City during a 3-month period in 1998; the serotype 14
strains were detected in Howard County in 3 different
years.
The incidence of invasive pneumococcal disease signif-
icantly increased from 1995 to 1999 before dramatically
decreasing from 1999 to 2001. From 1995 to 1999, the
overall rates of erythromycin-nonsusceptible S. pneumoni-
ae and mefE-associated disease increased, and then stabi-
lized from 1999 to 2001 (Table). While the overall rates of
erythromycin-nonsusceptible S. pneumoniae were stable,
the proportion of pneumococcal strains with reduced sus-
ceptibility to erythromycin increased from 5.1% (26/510)
in 1995 to 13.6% (77/567) in 2001 (p<0.01). Moreover, the
proportion of erythromycin-nonsusceptible S. pneumoniae
strains carrying the mefE gene with an erythromycin MIC
>16 µg/mL increased from 0% (0/12) in 1995 to 12.3%
(8/65) in 2001 (χ2 for linear trend, p = 0.02). The propor-
tion of erythromycin-nonsusceptible S. pneumoniae strains
carrying the mefE gene increased from 48.0% (12/25) in
1995 to 85.5% (65/76) in 2001 (p<0.01). Of the erythro-
mycin-nonsusceptible S. pneumoniae strains, the propor-
tion of mefE-carrying strains that were penicillin-
nonsusceptible S. pneumoniae rose from 20.0% (5/25) in
1995 to 72.4% (55/76) in 2001 (p<0.01). In 3 counties, in
both age groups, in both races, and during both seasons,
the proportion of mefE-carrying strains increased from
1995 to 2001 (Figure; p values for all analyses were
<0.02). Sixty-nine percent (182/263) of the mefE-carrying
strains were related to 4 international clones (percent
serotype): 30.0% England14-9 clone (100% 14); 16.0%
Spain23F-1 clone (83.3% 23F); 14.1% Spain9V-3 clone
(97.3% 9V); and 9.1% Taiwan19F-14clone (95.8% 19F). 
Among children <5 years old, the incidence of erythro-
mycin-nonsusceptible S. pneumoniae increased from 1995
to 1999 before declining by 53.6% (p = 0.03) between
1999 and 2001. Likewise, the incidence of mefE-associat-
ed disease rose in the 1990s before decreasing by 51.5%
from 1999 to 2001 (p = 0.07). The rates of disease due to
strains related to the England14-9 clone mirrored the age-
specific trends from 1995 to 2001 (p<0.05; Table). In con-
trast, in persons >5 years of age, the rate of
erythromycin-nonsusceptible  S. pneumoniae disease
remained stable after increasing in the 1990s. From 1999
to 2001, the rate of mefE-associated resistance increased
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-9 clone partially accounted for this increase. 
Conclusions
The incidence of invasive disease in the Baltimore met-
ropolitan area increased in the 1990s before declining from
1999 to 2001 (13). Likewise, the rate of invasive erythro-
mycin-nonsusceptible S. pneumoniae disease increased in
the 1990s (1). From 1999 to 2001, the overall incidence of
erythromycin-nonsusceptible  S. pneumoniae disease and
mefE-associated disease stabilized. The proportion of
erythromycin-nonsusceptible S. pneumoniae strains carry-
ing the mefE gene dramatically increased from 1995 to
2001. The increase in the proportion of erythromycin-non-
susceptible S. pneumoniae strains carrying the mefE gene
over time was detected in patients residing in all 3 geo-
graphic locations, from both races, from both age groups,
and during both the respiratory and nonrespiratory seasons. 
Both the incidence of invasive erythromycin-nonsus-
ceptible S. pneumoniae disease and mefE-associated dis-
ease declined by >50% from 1999 to 2001 in children <5
years of age. This decrease was partially due to serotype 14
strains related to the England14-9 clone. Strains related to
this clone may also account for the substantial decrease in
macrolide-resistant serotype 14 infections noted in Atlanta
(4). In contrast to the Atlanta study, the rates of mefE-asso-
ciated disease increased among persons >5 years. The dif-
ferences in rates detected in Baltimore compared to Atlanta
may reflect regional variation and the inclusion of 2002 in
the Atlanta analysis (4). In this study, the decrease in the
incidence of erythromycin-nonsusceptible S. pneumoniae
in children may have been due to variation in antimicrobial
drug use or to introduction of PCV7.
In summary, after increasing in the 1990s, the rates of
invasive erythromycin-nonsusceptible S. pneumoniae dis-
ease stabilized overall and decreased in children from 1999
to 2001. This remarkable decline was most likely due to
PCV7, although differential antimicrobial drugs may have
been a contributor. Unfortunately, the lack of decline in the
rate of invasive erythromycin-nonsusceptible S. pneumoni-
ae infections among persons >5 years of age, coupled with
the marked increase in dual resistance and the increase in
the proportion with erythromycin MICs >16 µg/mL from
1995 to 2001 (14), is cause for concern. Public health ini-
tiatives that focus on judicious use of antimicrobial drugs
and the PCV7 vaccine (13) may be beneficial in slowing
these trends (15).
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